Physician profile
Tamara R Postlethwait
NPI 1003325150
$1,424.62
in general payments reported to CMS, 2019-2025
10 companies · $418 in 2025
The $418 reported for 2025 was more than what a typical Family provider received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2023: $391 · 2024: $616 · 2025: $418.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,425.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,424.62 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $943.70 | 2023-2025 | Enbrel, Otezla, Otezla |
| Ucb, INC. | $103.09 | 2023-2025 | Cimzia, Bimzelx |
| Ani Pharmaceuticals, INC. | $98.00 | 2023-2025 | Purified Cortrophin Gel |
| Astrazeneca Pharmaceuticals LP | $70.94 | 2023-2024 | Saphnelo |
| Novartis Pharmaceuticals Corporation | $69.95 | 2025 | |
| Abbvie INC. | $60.82 | 2023-2024 | |
| Alexion Pharmaceuticals, INC. | $22.52 | 2025 | Strensiq |
| Pfizer INC. | $19.58 | 2025 | |
| Horizon Therapeutics Plc | $18.59 | 2023 | Krystexxa |
| Lilly USA, LLC | $17.43 | 2024 | Taltz |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Tamara Postlethwait listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.